JP6777757B2 - 癌検出のためのヌクレオソーム−転写因子複合体の使用 - Google Patents

癌検出のためのヌクレオソーム−転写因子複合体の使用 Download PDF

Info

Publication number
JP6777757B2
JP6777757B2 JP2018549812A JP2018549812A JP6777757B2 JP 6777757 B2 JP6777757 B2 JP 6777757B2 JP 2018549812 A JP2018549812 A JP 2018549812A JP 2018549812 A JP2018549812 A JP 2018549812A JP 6777757 B2 JP6777757 B2 JP 6777757B2
Authority
JP
Japan
Prior art keywords
cancer
nucleosome
tissue
transcription factor
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018549812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510974A (ja
JP2019510974A5 (enExample
Inventor
ビンセント ミカレフ ジャコブ
ビンセント ミカレフ ジャコブ
レイス‐フィルホ ジョルジ
レイス‐フィルホ ジョルジ
Original Assignee
ベルジアン ボリション エスピーアールエル
ベルジアン ボリション エスピーアールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55968658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6777757(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ベルジアン ボリション エスピーアールエル, ベルジアン ボリション エスピーアールエル filed Critical ベルジアン ボリション エスピーアールエル
Publication of JP2019510974A publication Critical patent/JP2019510974A/ja
Publication of JP2019510974A5 publication Critical patent/JP2019510974A5/ja
Application granted granted Critical
Publication of JP6777757B2 publication Critical patent/JP6777757B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018549812A 2016-03-22 2017-03-22 癌検出のためのヌクレオソーム−転写因子複合体の使用 Active JP6777757B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1604806.8 2016-03-22
GBGB1604806.8A GB201604806D0 (en) 2016-03-22 2016-03-22 Method of identifying a cancer of unknown origin
PCT/EP2017/056851 WO2017162755A1 (en) 2016-03-22 2017-03-22 Use of nucleosome-transcription factor complexes for cancer detection

Publications (3)

Publication Number Publication Date
JP2019510974A JP2019510974A (ja) 2019-04-18
JP2019510974A5 JP2019510974A5 (enExample) 2020-08-27
JP6777757B2 true JP6777757B2 (ja) 2020-10-28

Family

ID=55968658

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018549812A Active JP6777757B2 (ja) 2016-03-22 2017-03-22 癌検出のためのヌクレオソーム−転写因子複合体の使用

Country Status (12)

Country Link
US (1) US20200363418A1 (enExample)
EP (3) EP3433616B2 (enExample)
JP (1) JP6777757B2 (enExample)
KR (2) KR102246699B1 (enExample)
CN (1) CN109313192B (enExample)
AU (1) AU2017238442A1 (enExample)
CA (1) CA3018428C (enExample)
ES (2) ES2861440T5 (enExample)
GB (1) GB201604806D0 (enExample)
MY (1) MY187655A (enExample)
SG (1) SG11201807991QA (enExample)
WO (1) WO2017162755A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202238131A (zh) 2020-11-25 2022-10-01 比利時商比利時意志有限公司 測量無細胞核蛋白染色質片段之方法
TW202242145A (zh) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 核小體耗盡循環無細胞染色質片段之轉錄因子結合位點分析
TW202242130A (zh) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 循環轉錄因子分析
WO2023048509A1 (ko) * 2021-09-24 2023-03-30 주식회사 온코크로스 종양의 원발부위 결정 방법
TW202530419A (zh) 2023-10-04 2025-08-01 比利時商比利時意志有限公司 Pcr方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003535580A (ja) * 2000-03-27 2003-12-02 トーマス ジェファーソン ユニバーシティ 高特異性マーカー検出
ES2297011T3 (es) * 2001-09-14 2008-05-01 F. Hoffmann-La Roche Ag Diagnostico diferencial de los trastornos del metabolismo del hierro por medio de tres parametros independientes y recomendaciones para el tratamiento de estos trastornos del metabolismo del hierro.
US7248921B2 (en) * 2003-06-02 2007-07-24 Cameron Health, Inc. Method and devices for performing cardiac waveform appraisal
US20040018525A1 (en) * 2002-05-21 2004-01-29 Bayer Aktiengesellschaft Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma
US20040236188A1 (en) * 2003-05-19 2004-11-25 Ge Medical Systems Information Method and apparatus for monitoring using a mathematical model
WO2007025231A2 (en) * 2005-08-26 2007-03-01 The Trustees Of The University Of Pennsylvania Methods using snail transcriptional repressor
US20090298097A1 (en) * 2007-07-17 2009-12-03 Harris Pamela J Methods for the diagnosis of lung cancer
WO2010001933A1 (ja) * 2008-07-01 2010-01-07 学校法人日本大学 標的遺伝子特異的ヒストン修飾制御剤
MY148542A (en) * 2009-06-15 2013-04-30 Cancer Res Initiatives Foundation A method for the assessment of cancer in a biological sample obtained from a subject
EP2270510A1 (en) * 2009-07-02 2011-01-05 EMBL (European Molecular Biology Laboratory) Diagnostic method for predicting the risk of cancer recurrence based on Histone macroH2A isoforms
GB201115098D0 (en) * 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
GB201115095D0 (en) * 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
SG10201604081YA (en) * 2011-12-07 2016-07-28 Singapore Volition Pte Ltd Method for detecting nucleosome adducts
GB201303576D0 (en) 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for predicting therapy efficacy using nucleosome structure biomarkers

Also Published As

Publication number Publication date
EP4270007A2 (en) 2023-11-01
CN109313192A (zh) 2019-02-05
KR20190013707A (ko) 2019-02-11
KR20210049954A (ko) 2021-05-06
ES2951136T3 (es) 2023-10-18
CA3018428A1 (en) 2017-09-28
CA3018428C (en) 2024-03-19
CN109313192B (zh) 2022-07-26
WO2017162755A1 (en) 2017-09-28
MY187655A (en) 2021-10-07
JP2019510974A (ja) 2019-04-18
EP3433616B2 (en) 2024-07-24
SG11201807991QA (en) 2018-10-30
ES2861440T5 (en) 2025-02-05
AU2017238442A1 (en) 2018-10-11
KR102246699B1 (ko) 2021-05-04
EP3839513C0 (en) 2023-06-14
US20200363418A1 (en) 2020-11-19
EP3433616B1 (en) 2020-12-30
EP3839513A1 (en) 2021-06-23
ES2861440T3 (es) 2021-10-06
KR102369544B1 (ko) 2022-03-03
EP3433616A1 (en) 2019-01-30
GB201604806D0 (en) 2016-05-04
EP3839513B1 (en) 2023-06-14
EP4270007A3 (en) 2023-12-20

Similar Documents

Publication Publication Date Title
JP6263474B2 (ja) ヌクレオソームアダクト検出法
JP6777757B2 (ja) 癌検出のためのヌクレオソーム−転写因子複合体の使用
EP2962112B1 (en) Method for predicting therapy efficacy using nucleosome structure biomarkers
TW201930881A (zh) 大腸直腸腺瘤之檢測及治療方法
HK40055426A (en) Use of dna-transcription factor complexes for cancer detection
TWI757285B (zh) 癌症偵測方法
HK40003771B (en) Use of nucleosome-transcription factor complexes for cancer detection
HK1249176B (en) Method for detecting nucleosome adducts
HK1202926B (en) Method for detecting nucleosome adducts

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200714

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200714

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200902

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200915

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201008

R150 Certificate of patent or registration of utility model

Ref document number: 6777757

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250